Nilo Therapeutics emerged from academic labs with a $101 million Series A to build therapeutics that modulate neural circuits to restore immune homeostasis. Founders include Columbia’s Charles Zuker, Yale’s Ruslan Medzhitov and Harvard’s Steve Liberles; the company said it will develop programs for autoimmune and inflammatory diseases by targeting “master regulator” vagal and other neuro‑immune pathways. The financing was led by The Column Group, DCVC Bio and Lux Capital, with participation from the Gates Foundation and Alexandria. Nilo plans to expand labs and preclinical pipelines in New York, aiming to translate circuit‑level biology into systemic immunomodulators — a high‑risk, high‑reward strategy that could create a new therapeutic class if mechanisms and delivery prove tractable.